Kura Oncology Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Kura Oncology stock has a consensus rating of "Strong Buy" and an average price target of $31.17. The average 1-year stock price forecast is 213.90% higher than the current stock price, while the lowest is $15 (+51.06%) and the highest is $76 (+665.36%).

Price Target: $31.17 (+213.90%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$15	$31.17	$28	$76
Change	+51.06%	+213.90%	+181.97%	+665.36%

Analyst Ratings

The average analyst rating for Kura Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	11	11	11	12	12	12
Buy	2	2	2	2	2	2
Hold	2	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	14	14	15	15	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst Wedbush No rating	Wedbush	Buy Reiterates $36	Buy	Reiterates	$36	+262.54%	Jun 15, 2026
Charles Zhu LifeSci Capital	LifeSci Capital	Buy Maintains $28	Buy	Maintains	$28	+181.97%	Jun 15, 2026
Unknown Analyst Jefferies No rating	Jefferies	Buy Maintains $28	Buy	Maintains	$28	+181.97%	Jun 15, 2026
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Buy Reiterates $40	Buy	Reiterates	$40	+302.82%	Jun 15, 2026
Daniel Brims Lake Street	Lake Street	Buy Initiates $23	Buy	Initiates	$23	+131.62%	Jun 5, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

94.90M

from 67.48M

40.63%

from 67.48M

Revenue Next Year

214.56M

from 94.90M

126.09%

from 94.90M

EPS This Year

-3.54

from -3.18

EPS Next Year

-2.65

from -3.54

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	53.88M	67.48M	94.90M
Revenue Growth	-	-	-	-	25.24%	40.63%
Gross Profit	-	-92.81M	-115.24M	-116.08M	-183.65M	93.26M
Gross Margin	-	-	-	-215.44%	-272.15%	98.27%
Operating Income	-131.26M	-139.87M	-165.80M	-193.20M	-303.63M	-327.26M
Net Income	-130.47M	-135.84M	-152.63M	-173.98M	-278.67M	-313.70M
EPS	-	-	-	-	-3.18	-3.54
Free Cash Flow	-60.41M	-63.67M	-63.90M	-55.93M	-141.73M	-216.50M
No. Analysts	-	-	-	-	-	14

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	131.2M
Avg	94.9M
Low	72.6M

Revenue Growth

Revenue Growth	2026	2027	2028
High	94.4%
Avg	40.6%
Low	7.6%

EPS Forecast

EPS	2026	2027	2028
High	-3.33
Avg	-3.54
Low	-3.72

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-